KDR and hepatocellular carcinoma: In a meta‐analysis (n = 9446) examining the incidence of proteinuria in clinical trials of five VEGFR‐TKIs (regorafenib, vandetanib, cabozantinib, lenvatinib, and axitinib) in patients with multiple carcinomas, including mRCC and HCC, the use of VEGFR‐TKIs significantly increased the relative risk (RR) of all‐grade proteinuria (RR 2.35, 95% confidence interval [CI] 1.69–3.27, p < 0.001) and high‐grade proteinuria (RR 3.70, 95% CI 2.09–6.54, p < 0.001).2